Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine

John H. Beigel, Jocelyn Voell, Chiung Yu Huang, Peter D. Burbelo, H. Clifford Lane

Research output: Contribution to journalArticle

Abstract

Background. H5N1 avian influenza represents an episodic zoonotic disease with the potential to cause a pandemic, and antiviral resistance is of considerable concern. We sought to generate high-titer H5N1 antibodies in healthy volunteers for the purpose of developing hyperimmune intravenous immunoglobulin. Methods. We conducted a dose-escalating, unblinded clinical trial involving 75 subjects aged 18-59 years. Three cohorts of twenty-five subjects were enrolled sequentially and received 90, 120, or 180 μg of H5N1 A/Vietnam/ 1203/04 vaccine in 4 doses administered ∼28 days apart. Results. No statistically significant dose-related increases in the geometric mean titers (GMTs) of serum hemagglutination inhibition antibody were observed when the 90-μg, 120-μg, and 180-μg cohorts were compared. When the cohorts were analyzed together to determine the effect of additional vaccinations, the GMTs of hemagglutination inhibition antibody after the first, second, third, and fourth vaccinations were 1:15.7,1:22.2,1:36.0, and 1:32.0, respectively (first vaccination vs. baseline, P

Original languageEnglish (US)
Pages (from-to)501-509
Number of pages9
JournalJournal of Infectious Diseases
Volume200
Issue number4
DOIs
StatePublished - Aug 15 2009
Externally publishedYes

Fingerprint

Human Influenza
Vaccination
Vaccines
Hemagglutination
Safety
Antibodies
Influenza in Birds
Vietnam
Intravenous Immunoglobulins
Zoonoses
Pandemics
Antiviral Agents
Healthy Volunteers
Clinical Trials
Serum

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Beigel, J. H., Voell, J., Huang, C. Y., Burbelo, P. D., & Clifford Lane, H. (2009). Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. Journal of Infectious Diseases, 200(4), 501-509. https://doi.org/10.1086/599992

Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. / Beigel, John H.; Voell, Jocelyn; Huang, Chiung Yu; Burbelo, Peter D.; Clifford Lane, H.

In: Journal of Infectious Diseases, Vol. 200, No. 4, 15.08.2009, p. 501-509.

Research output: Contribution to journalArticle

Beigel, JH, Voell, J, Huang, CY, Burbelo, PD & Clifford Lane, H 2009, 'Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine', Journal of Infectious Diseases, vol. 200, no. 4, pp. 501-509. https://doi.org/10.1086/599992
Beigel, John H. ; Voell, Jocelyn ; Huang, Chiung Yu ; Burbelo, Peter D. ; Clifford Lane, H. / Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. In: Journal of Infectious Diseases. 2009 ; Vol. 200, No. 4. pp. 501-509.
@article{45a1d1f9652c49ca86153b5ae559fbf2,
title = "Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine",
abstract = "Background. H5N1 avian influenza represents an episodic zoonotic disease with the potential to cause a pandemic, and antiviral resistance is of considerable concern. We sought to generate high-titer H5N1 antibodies in healthy volunteers for the purpose of developing hyperimmune intravenous immunoglobulin. Methods. We conducted a dose-escalating, unblinded clinical trial involving 75 subjects aged 18-59 years. Three cohorts of twenty-five subjects were enrolled sequentially and received 90, 120, or 180 μg of H5N1 A/Vietnam/ 1203/04 vaccine in 4 doses administered ∼28 days apart. Results. No statistically significant dose-related increases in the geometric mean titers (GMTs) of serum hemagglutination inhibition antibody were observed when the 90-μg, 120-μg, and 180-μg cohorts were compared. When the cohorts were analyzed together to determine the effect of additional vaccinations, the GMTs of hemagglutination inhibition antibody after the first, second, third, and fourth vaccinations were 1:15.7,1:22.2,1:36.0, and 1:32.0, respectively (first vaccination vs. baseline, P",
author = "Beigel, {John H.} and Jocelyn Voell and Huang, {Chiung Yu} and Burbelo, {Peter D.} and {Clifford Lane}, H.",
year = "2009",
month = "8",
day = "15",
doi = "10.1086/599992",
language = "English (US)",
volume = "200",
pages = "501--509",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine

AU - Beigel, John H.

AU - Voell, Jocelyn

AU - Huang, Chiung Yu

AU - Burbelo, Peter D.

AU - Clifford Lane, H.

PY - 2009/8/15

Y1 - 2009/8/15

N2 - Background. H5N1 avian influenza represents an episodic zoonotic disease with the potential to cause a pandemic, and antiviral resistance is of considerable concern. We sought to generate high-titer H5N1 antibodies in healthy volunteers for the purpose of developing hyperimmune intravenous immunoglobulin. Methods. We conducted a dose-escalating, unblinded clinical trial involving 75 subjects aged 18-59 years. Three cohorts of twenty-five subjects were enrolled sequentially and received 90, 120, or 180 μg of H5N1 A/Vietnam/ 1203/04 vaccine in 4 doses administered ∼28 days apart. Results. No statistically significant dose-related increases in the geometric mean titers (GMTs) of serum hemagglutination inhibition antibody were observed when the 90-μg, 120-μg, and 180-μg cohorts were compared. When the cohorts were analyzed together to determine the effect of additional vaccinations, the GMTs of hemagglutination inhibition antibody after the first, second, third, and fourth vaccinations were 1:15.7,1:22.2,1:36.0, and 1:32.0, respectively (first vaccination vs. baseline, P

AB - Background. H5N1 avian influenza represents an episodic zoonotic disease with the potential to cause a pandemic, and antiviral resistance is of considerable concern. We sought to generate high-titer H5N1 antibodies in healthy volunteers for the purpose of developing hyperimmune intravenous immunoglobulin. Methods. We conducted a dose-escalating, unblinded clinical trial involving 75 subjects aged 18-59 years. Three cohorts of twenty-five subjects were enrolled sequentially and received 90, 120, or 180 μg of H5N1 A/Vietnam/ 1203/04 vaccine in 4 doses administered ∼28 days apart. Results. No statistically significant dose-related increases in the geometric mean titers (GMTs) of serum hemagglutination inhibition antibody were observed when the 90-μg, 120-μg, and 180-μg cohorts were compared. When the cohorts were analyzed together to determine the effect of additional vaccinations, the GMTs of hemagglutination inhibition antibody after the first, second, third, and fourth vaccinations were 1:15.7,1:22.2,1:36.0, and 1:32.0, respectively (first vaccination vs. baseline, P

UR - http://www.scopus.com/inward/record.url?scp=69149086060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69149086060&partnerID=8YFLogxK

U2 - 10.1086/599992

DO - 10.1086/599992

M3 - Article

VL - 200

SP - 501

EP - 509

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -